Douglas Pharmaceuticals announces positive top-line results from Phase 2 trial of R-107 in subjects with Treatment Resistant Depression

Douglas Pharmaceuticals Ltd today announced positive top-line data from its multinational, randomized, placebo-controlled, double-blind Phase 2 study of R-107 designed to investigate the efficacy and safety of R-107 (ketamine 30, 60, 120 or 180 mg) versus placebo for TRD.